{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:16:49Z","timestamp":1773976609415,"version":"3.50.1"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10604-8","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:12:18Z","timestamp":1773972738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostics in cardio-oncology: a focus on anthracyclines"],"prefix":"10.1007","volume":"31","author":[{"given":"Ashot","family":"Avagimyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Pogosova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Fogacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinaida","family":"Djndoyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lusine","family":"Mkrtchyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysa","family":"Rezabakhsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arrigo","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Gherbesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Carugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzieh","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Spadafora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo Lo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Perone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davood","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azin","family":"Alizadehasl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Moudgil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Prattichizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Biondi-Zoccai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Asteggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizal","family":"Sarrafzadegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"3","key":"10604_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102389","volume":"49","author":"S Imran","year":"2024","unstructured":"Imran S, Rao MS, Shah MH et al (2024) Evolving perspectives in reverse cardio-oncology: a review of current status, pathophysiological insights, and future directives. Curr Probl Cardiol 49(3):102389. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102389","journal-title":"Curr Probl Cardiol"},{"issue":"8","key":"10604_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101227","volume":"48","author":"S Shi","year":"2023","unstructured":"Shi S, Lv J, Chai R et al (2023) Opportunities and challenges in cardio-oncology: a bibliometric analysis from 2010 to 2022. Curr Probl Cardiol 48(8):101227. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101227","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10604_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101435","volume":"48","author":"T Ahmed","year":"2023","unstructured":"Ahmed T, Marmagkiolis K, Ploch M et al (2023) The year in cardio-oncology 2022. Curr Probl Cardiol 48(1):101435. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101435","journal-title":"Curr Probl Cardiol"},{"key":"10604_CR4","doi-asserted-by":"publisher","unstructured":"Pogosova NV, Boytsov SA, Preventive cardiology state of problem perspectives of development. Kardiologiia. 2024;64(1):4\u201313.\u00a0 https:\/\/doi.org\/10.18087\/cardio.2024.1.n2636","DOI":"10.18087\/cardio.2024.1.n2636"},{"key":"10604_CR5","doi-asserted-by":"publisher","unstructured":"Avagimyan A, Pogosova N, Kakturskiy L, et al. Doxorubicin-related cardiotoxicity: review of fundamental pathways of cardiovascular system injury. Cardiovasc Pathol. 2024;73:107683. doi: https:\/\/doi.org\/10.1016\/j.carpath.2024.107683","DOI":"10.1016\/j.carpath.2024.107683"},{"issue":"1","key":"10604_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaccao.2023.01.004","volume":"5","author":"MC LeCompte","year":"2023","unstructured":"LeCompte MC, Brawley OW (2023) The cause of death in patients with cancer. JACC CardioOncol 5(1):67\u201369. https:\/\/doi.org\/10.1016\/j.jaccao.2023.01.004","journal-title":"JACC CardioOncol"},{"issue":"1 Pt C","key":"10604_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102187","volume":"49","author":"S Khaled","year":"2024","unstructured":"Khaled S, Abdelkhalek S, Aljuwaybiri R et al (2024) Cardiac dysfunction and their determinants in patients treated for breast cancer and lymphoma: a cardio-oncology center experience. Curr Probl Cardiol 49(1 Pt C):102187. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102187","journal-title":"Curr Probl Cardiol"},{"key":"10604_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.hlc.2023.04.301","volume":"33","author":"AL Sverdlov","year":"2024","unstructured":"Sverdlov AL, Koczwara B, Cehic DA, Clinical Oncology Society of Australia (COSA)\u2013Cardiac Society of Australia and New Zealand (CSANZ) Cardio-Oncology Working Group et al (2024) When cancer and cardiovascular disease intersect: the challenge and the opportunity of cardio-oncology. Heart Lung Circ 33:558\u2013563. https:\/\/doi.org\/10.1016\/j.hlc.2023.04.301","journal-title":"Heart Lung Circ"},{"key":"10604_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-025-00369-8","volume":"11","author":"JD Bennetts","year":"2025","unstructured":"Bennetts JD, Williams TD, Beavers GJ et al (2025) The cardio-oncology multidisciplinary team: beyond the basics. Cardio-Oncol 11:69. https:\/\/doi.org\/10.1186\/s40959-025-00369-8","journal-title":"Cardio-Oncol"},{"issue":"4","key":"10604_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101591","volume":"48","author":"T Abdul-Rahman","year":"2023","unstructured":"Abdul-Rahman T, Dunham A, Huang H et al (2023) Chemotherapy induced cardiotoxicity: a state-of-the-art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics. Curr Probl Cardiol 48(4):101591. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101591","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10604_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.20538\/1682-0363-2017-3-127-136","volume":"16","author":"AT Teplyakov","year":"2017","unstructured":"Teplyakov AT, Shilov SN, Popova AA et al (2017) The cardiovascular system in patients with anthracycline cardiomiopathy. Bull Sib Med 16(3):127\u2013136. https:\/\/doi.org\/10.20538\/1682-0363-2017-3-127-136","journal-title":"Bull Sib Med"},{"key":"10604_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.35401\/2541-9897-2023-8-4-6-14","volume":"4","author":"AA Avagimyan","year":"2023","unstructured":"Avagimyan AA, Trofimenko AI, Sheibani M et al (2023) Comparison of cardioprotective effects of Dapagliflozin and Trimetazidine in the model of Doxorubicin-Cyclophosphamide cardiotoxicity. Innovative Medicine of Kuban 4:6\u201314. https:\/\/doi.org\/10.35401\/2541-9897-2023-8-4-6-14","journal-title":"Innovative Medicine of Kuban"},{"issue":"5","key":"10604_CR13","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.cpcardiol.2021.100909","volume":"47","author":"A Avagimyan","year":"2022","unstructured":"Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K et al (2022) Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol 47(5):100909. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100909","journal-title":"Curr Probl Cardiol"},{"key":"10604_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ijcard.2020.06.003","volume":"317","author":"AK Ghosh","year":"2020","unstructured":"Ghosh AK (2020) Cardio-oncology - more than just cardiac complications of cancer treatment. Int J Cardiol 317:174\u2013175. https:\/\/doi.org\/10.1016\/j.ijcard.2020.06.003","journal-title":"Int J Cardiol"},{"issue":"1","key":"10604_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jaccao.2024.01.001","volume":"6","author":"L De Michieli","year":"2024","unstructured":"De Michieli L, Jaffe A (2024) Cancer therapy\u2013related cardiac dysfunction: expanding the horizon of cardiac troponin in clinical practice. J Am Coll Cardiol CardioOnc 6(1):96\u201398. https:\/\/doi.org\/10.1016\/j.jaccao.2024.01.001","journal-title":"J Am Coll Cardiol CardioOnc"},{"issue":"1","key":"10604_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40959-021-00110-1","volume":"7","author":"RA de Boer","year":"2021","unstructured":"de Boer RA, Aboumsallem JP, Bracun V et al (2021) A new classification of cardio-oncology syndromes. Cardiooncology 7(1):24 Published 2021 Jun 21. https:\/\/doi.org\/10.1186\/s40959-021-00110-1","journal-title":"Cardiooncology"},{"issue":"3","key":"10604_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/eurheartj\/ehae624","volume":"46","author":"LE Butel-Simoes","year":"2025","unstructured":"Butel-Simoes LE, Ngo DTM, Sverdlov AL (2025) Navigating cardiotoxicity risk in cancer therapy: the importance of the HFA-ICOS score. Eur Heart J 46(3):285\u2013287. https:\/\/doi.org\/10.1093\/eurheartj\/ehae624","journal-title":"Eur Heart J"},{"issue":"18","key":"10604_CR18","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J L\u00f3pez-Send\u00f3n","year":"2020","unstructured":"L\u00f3pez-Send\u00f3n J, \u00c1lvarez-Ortega C, Zamora Au\u00f1on P et al (2020) Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 41(18):1720\u20131729. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa006","journal-title":"Eur Heart J"},{"issue":"18","key":"10604_CR19","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/eurjpc\/zwad243","volume":"30","author":"A Galimzhanov","year":"2023","unstructured":"Galimzhanov A, Istanbuly S, Tun HN et al (2023) Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis. Eur J Prev Cardiol 30(18):2018\u20132031. https:\/\/doi.org\/10.1093\/eurjpc\/zwad243","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"10604_CR20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/eurheartj\/ehad196","volume":"44","author":"AR Lyon","year":"2023","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2023) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [published correction appears in. Eur Heart J 44(18):1621 https:\/\/doi.org\/10.1093\/eurheartj\/ehad196","journal-title":"Eur Heart J"},{"key":"10604_CR21","doi-asserted-by":"publisher","unstructured":"Maselli-Schoueri JH, Saibil SD, Gabriel da Silva Negrini V et al (2026) Beyond the hazard ratio: rethinking survival reporting in cardio-oncology with restricted mean survival time. JACC CardioOncol 8(1):90\u201392. https:\/\/doi.org\/10.1016\/j.jaccao.2025.11.003","DOI":"10.1016\/j.jaccao.2025.11.003"},{"issue":"5","key":"10604_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/eurheartj\/ehac813","volume":"44","author":"J Herrmann","year":"2023","unstructured":"Herrmann J, Lpez-Fernndez T, Lyon AR (2023) The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology [published correction appears in Eur Heart J. 2023 May 21;44(20):1806. doi: 10.1093\/eurheartj\/ehad090]. Eur Heart J 44(5):348\u2013350. https:\/\/doi.org\/10.1093\/eurheartj\/ehac813","journal-title":"Eur Heart J"},{"issue":"1","key":"10604_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-025-10575-2","volume":"31","author":"AA Avagimyan","year":"2025","unstructured":"Avagimyan AA, Pogosova N, Fogacci F et al (2025) Pharmacological prevention in cardio-oncology: from bench-to-bedside. Heart Fail Rev 31(1):7. https:\/\/doi.org\/10.1007\/s10741-025-10575-2","journal-title":"Heart Fail Rev"},{"key":"10604_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.670479","volume":"12","author":"EY Podyacheva","year":"2021","unstructured":"Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG (2021) Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician. Front Pharmacol 12:670479. https:\/\/doi.org\/10.3389\/fphar.2021.670479","journal-title":"Front Pharmacol"},{"key":"10604_CR25","doi-asserted-by":"publisher","first-page":"107526","DOI":"10.1016\/j.vph.2025.107526","volume":"160","author":"A Avagimyan","year":"2025","unstructured":"Avagimyan A, Madonna R, Sheibani M et al (2025) Translational aspects of doxorubicin-induced cardiotoxicity: What we have omitted for the past decades? Vascul Pharmacol 160:107526. https:\/\/doi.org\/10.1016\/j.vph.2025.107526","journal-title":"Vascul Pharmacol"},{"issue":"24","key":"10604_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413567","volume":"25","author":"J Szponar","year":"2024","unstructured":"Szponar J, Ciechanski E, Ciechanska M et al (2024) Evolution of theories on doxorubicin-induced late cardiotoxicity-role of topoisomerase. Int J Mol Sci 25(24):13567. https:\/\/doi.org\/10.3390\/ijms252413567","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10604_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-87442-5","volume":"15","author":"C Kelly","year":"2025","unstructured":"Kelly C, Kiltschewskij DJ, Leong AJW, Haw TJ, Croft AJ, Balachandran L, Chen D, Bond DR, Lee HJ, Cairns MJ, Sverdlov AL, Ngo DTM (2025) Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities: transcriptomic and epigenetic profiling. Sci Rep 15(5):4395. https:\/\/doi.org\/10.1038\/s41598-025-87442-5","journal-title":"Sci Rep"},{"issue":"5","key":"10604_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.hlc.2024.01.013","volume":"33","author":"L Balachandran","year":"2024","unstructured":"Balachandran L, Haw TJ, Leong AJW, Croft AJ, Chen D, Kelly C, Sverdlov AL, Ngo DTM (2024) Cancer therapies and cardiomyocyte viability: which drugs are directly cardiotoxic? Heart Lung Circ 33(5):747\u2013752. https:\/\/doi.org\/10.1016\/j.hlc.2024.01.013","journal-title":"Heart Lung Circ"},{"key":"10604_CR29","doi-asserted-by":"crossref","unstructured":"Avagimyan A, Kaktursky L (2022) Cardiotoxicity of cyclophosphamide: current state of the problem. Exp Clin Med Georg 310.52340\/jecm.2022.03.14","DOI":"10.52340\/jecm.2022.03.14"},{"issue":"7","key":"10604_CR30","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 23(7):vii155\u2013vii166. https:\/\/doi.org\/10.1093\/annonc\/mds293","journal-title":"Ann Oncol"},{"issue":"5","key":"10604_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100909","volume":"47","author":"A Avagimyan","year":"2022","unstructured":"Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N (2022) Anthracycline associated disturbances of cardiovascular homeostasis. Curr Probl Cardiol 47(5):100909. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100909","journal-title":"Curr Probl Cardiol"},{"key":"10604_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07574-0","author":"A Nagy","year":"2024","unstructured":"Nagy A, B\u00f6rzsei D, Hoffmann A et al (2024) A comprehensive overview on chemotherapy-induced cardiotoxicity: insights into the underlying inflammatory and oxidative mechanisms. Cardiovasc Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-024-07574-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"10604_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.yjmcc.2025.07.015","volume":"206","author":"D Chen","year":"2025","unstructured":"Chen D, Croft AJ, Haw TJ, Kelly C, Balachandran L, Sverdlov AL, Ngo DTM (2025) Anti-cancer agent Olaparib ameliorates doxorubicin-induced cardiotoxicity in vitro and in vivo. J Mol Cell Cardiol 206:114\u2013126. https:\/\/doi.org\/10.1016\/j.yjmcc.2025.07.015","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10604_CR34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.1631","volume":"22","author":"L Michel","year":"2020","unstructured":"Michel L, Mincu RI, Mahabadi AA et al (2020) Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail 22(2):350\u2013361. https:\/\/doi.org\/10.1002\/ejhf.1631","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10604_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/life12081183","volume":"12","author":"V Sorodoc","year":"2022","unstructured":"Sorodoc V, Sirbu O, Lionte C et al (2022) The value of troponin as a biomarker of chemotherapy-induced cardiotoxicity. Life (Basel) 12(8):1183. https:\/\/doi.org\/10.3390\/life12081183","journal-title":"Life (Basel)"},{"issue":"8","key":"10604_CR36","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H et al (2014) Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 63(8):809\u2013816. https:\/\/doi.org\/10.1016\/j.jacc.2013.10.061","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10604_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"D Zardavas","year":"2017","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ et al (2017) Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a Herceptin adjuvant study cardiac marker substudy. J Clin Oncol 35(8):878\u2013884. https:\/\/doi.org\/10.1200\/JCO.2015.65.7916","journal-title":"J Clin Oncol"},{"issue":"11","key":"10604_CR38","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.18087\/cardio.2020.11.n1390","volume":"60","author":"DA Budanova","year":"2020","unstructured":"Budanova DA, Antyufeeva ON, Ilgisonis IS et al (2020) Kardiologiia 60(11):1390. https:\/\/doi.org\/10.18087\/cardio.2020.11.n1390","journal-title":"Kardiologiia"},{"issue":"5","key":"10604_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.18087\/cardio.2021.5.n1530","volume":"61","author":"MV Kozhevnikova","year":"2021","unstructured":"Kozhevnikova MV, Belenkov YN (2021) Kardiologiia 61(5):4\u201316. https:\/\/doi.org\/10.18087\/cardio.2021.5.n1530","journal-title":"Kardiologiia"},{"issue":"3","key":"10604_CR40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.18087\/cardio.2017.12.10065","volume":"62","author":"A Editorial","year":"2022","unstructured":"Editorial A Comments of the editorial board on the article The incidence of atrial infarction in patients with supraventricular arrhythmias (2022). Kardiologiia 62(3):1711. https:\/\/doi.org\/10.18087\/cardio.2017.12.10065","journal-title":"Kardiologiia"},{"issue":"5","key":"10604_CR41","doi-asserted-by":"publisher","DOI":"10.15829\/1560-4071-2020-3870","volume":"25","author":"Z Kobalava","year":"2020","unstructured":"Kobalava Z, Medovchshikov VV, Yeshniyazov NB (2020) Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data. Russ J Cardiol 25(5):3870. https:\/\/doi.org\/10.15829\/1560-4071-2020-3870","journal-title":"Russ J Cardiol"},{"issue":"3","key":"10604_CR42","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1007\/s13277-015-4183-7","volume":"37","author":"F De Iuliis","year":"2016","unstructured":"De Iuliis F, Salerno G, Taglieri L et al (2016) Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients. Tumour Biol 37(3):3379\u20133387. https:\/\/doi.org\/10.1007\/s13277-015-4183-7","journal-title":"Tumour Biol"},{"issue":"8","key":"10604_CR43","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1373\/clinchem.2005.050153","volume":"51","author":"MT Sandri","year":"2005","unstructured":"Sandri MT, Salvataci M, Cardinale D et al (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51(8):1405\u20131410. https:\/\/doi.org\/10.1373\/clinchem.2005.050153","journal-title":"Clin Chem"},{"issue":"23","key":"10604_CR44","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","volume":"101","author":"N Pavo","year":"2015","unstructured":"Pavo N, Raderer M, H\u00fclsmann M et al (2015) Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart 101(23):1874\u20131880. https:\/\/doi.org\/10.1136\/heartjnl-2015-307848","journal-title":"Heart"},{"issue":"5","key":"10604_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096736","volume":"9","author":"D Skovgaard","year":"2014","unstructured":"Skovgaard D, Hasbak P, Kjaer A (2014) BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. PLoS One 9(5):e96736. https:\/\/doi.org\/10.1371\/journal.pone.0096736","journal-title":"PLoS One"},{"issue":"2","key":"10604_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/biom14020199","volume":"14","author":"U Attanasio","year":"2024","unstructured":"Attanasio U, Di Sarro E, Tricarico L et al (2024) Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond. Biomolecules 14(2):199. https:\/\/doi.org\/10.3390\/biom14020199","journal-title":"Biomolecules"},{"key":"10604_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1396133","volume":"15","author":"C Tian","year":"2024","unstructured":"Tian C, Zhang H, Liu J, Xu M, Ma L (2024) GDF-15 is a potential candidate biomarker for an elevated risk of cardiotoxicity in breast cancer patients receiving neoadjuvant dual anti-HER2 therapy. Front Pharmacol 15:1396133. https:\/\/doi.org\/10.3389\/fphar.2024.1396133","journal-title":"Front Pharmacol"},{"issue":"13","key":"10604_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133290","volume":"15","author":"A Alexandraki","year":"2023","unstructured":"Alexandraki A, Papageorgiou E, Zacharia M et al (2023) New insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review. Cancers (Basel) 15(13):3290. https:\/\/doi.org\/10.3390\/cancers15133290","journal-title":"Cancers (Basel)"},{"key":"10604_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/2404806","volume":"2023","author":"F Masoudkabir","year":"2023","unstructured":"Masoudkabir F, Mohammadifard N, Mani A et al (2023) Shared lifestyle-related risk factors of cardiovascular disease and cancer: evidence for joint prevention. Sci World J 2023:2404806. https:\/\/doi.org\/10.1155\/2023\/2404806","journal-title":"Sci World J"},{"issue":"9","key":"10604_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094339","volume":"22","author":"EA Silveira","year":"2021","unstructured":"Silveira EA, da Silva Filho RR, Spexoto MCB et al (2021) The role of sarcopenic obesity in cancer and cardiovascular disease: a synthesis of the evidence on pathophysiological aspects and clinical implications. Int J Mol Sci 22(9):4339. https:\/\/doi.org\/10.3390\/ijms22094339","journal-title":"Int J Mol Sci"},{"key":"10604_CR51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.atherosclerosis.2017.06.001","volume":"263","author":"F Masoudkabir","year":"2017","unstructured":"Masoudkabir F, Sarrafzadegan N, Gotay C et al (2017) Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis 263:343\u2013351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.06.001","journal-title":"Atherosclerosis"},{"issue":"10","key":"10604_CR52","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.3390\/nu13103504","volume":"13","author":"EA Silveira","year":"2021","unstructured":"Silveira EA, Noll PRES, Mohammadifard N et al (2021) Which Diets Are Effective in Reducing Cardiovascular and Cancer Risk in Women with Obesity? Integr Rev Nutrients 13(10):3504 Published 2021 Oct 4. https:\/\/doi.org\/10.3390\/nu13103504","journal-title":"Integr Rev Nutrients"},{"issue":"17","key":"10604_CR53","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.3390\/nu14173499","volume":"14","author":"N Mohammadifard","year":"2022","unstructured":"Mohammadifard N, Haghighatdoost F, Rahimlou M et al (2022) The Effect of Ketogenic Diet on Shared Risk Factors of Cardiovascular Disease and Cancer. Nutrients 14(17):3499. https:\/\/doi.org\/10.3390\/nu14173499","journal-title":"Nutrients"},{"issue":"1","key":"10604_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13088","volume":"22","author":"EA Silveira","year":"2021","unstructured":"Silveira EA, Kliemann N, Noll M et al (2021) Visceral obesity and incident cancer and cardiovascular disease: an integrative review of the epidemiological evidence. Obes Rev 22(1):e13088. https:\/\/doi.org\/10.1111\/obr.13088","journal-title":"Obes Rev"},{"issue":"5","key":"10604_CR55","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ejheart.2004.12.008","volume":"7","author":"E Varol","year":"2005","unstructured":"Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7(5):840\u2013843. https:\/\/doi.org\/10.1016\/j.ejheart.2004.12.008","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10604_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/biom14020199","volume":"14","author":"U Attanasio","year":"2024","unstructured":"Attanasio U, Di Sarro E, Tricarico L et al (2024) Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond. Biomolecules 14(2):199. https:\/\/doi.org\/10.3390\/biom14020199","journal-title":"Biomolecules"},{"issue":"6","key":"10604_CR57","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/ejhf.531","volume":"18","author":"AA Voors","year":"2016","unstructured":"Voors AA, Anker SD, Cleland JG et al (2016) A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 18(6):716\u2013726. https:\/\/doi.org\/10.1002\/ejhf.531","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10604_CR58","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/joim.13053","volume":"288","author":"C Shi","year":"2020","unstructured":"Shi C, van der Wal HH, Sillj\u00e9 HHW et al (2020) Tumour biomarkers: association with heart failure outcomes. J Intern Med 288(2):207\u2013218. https:\/\/doi.org\/10.1111\/joim.13053","journal-title":"J Intern Med"},{"issue":"15","key":"10604_CR59","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.021069","volume":"10","author":"M Yamamoto","year":"2021","unstructured":"Yamamoto M, Hanatani S, Araki S et al (2021) HE4 predicts progressive fibrosis and cardiovascular events in patients with dilated cardiomyopathy. J Am Heart Assoc 10(15):e021069. https:\/\/doi.org\/10.1161\/JAHA.120.021069","journal-title":"J Am Heart Assoc"},{"key":"10604_CR60","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2147\/IJGM.S444680","volume":"17","author":"Y Tang","year":"2024","unstructured":"Tang Y, Hu Z, Liu Z et al (2024) HE4 serum levels are associated with poor prognosis in patients with acute heart failure combined with chronic kidney disease. Int J Gen Med 17:1273\u20131280. https:\/\/doi.org\/10.2147\/IJGM.S444680","journal-title":"Int J Gen Med"},{"issue":"1","key":"10604_CR61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jaccao.2022.01.095","volume":"4","author":"EE Liu","year":"2022","unstructured":"Liu EE, Suthahar N, Paniagua SM et al (2022) Association of cardiometabolic disease with cancer in the community. JACC: CardioOncology 4(1):69\u201381. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.095","journal-title":"JACC: CardioOncology"},{"issue":"5","key":"10604_CR62","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.15829\/1560-4071-2023-5452","volume":"28","author":"SA Boytsov","year":"2023","unstructured":"Boytsov SA, Pogosova NV, Ansheles AA et al (2023) Cardiovascular prevention 2022. Russian national guidelines. Russian J Cardiol 28(5):5452. https:\/\/doi.org\/10.15829\/1560-4071-2023-5452","journal-title":"Russian J Cardiol"},{"issue":"21","key":"10604_CR63","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/eurheartj\/ehaa177","volume":"41","author":"NA Chatterjee","year":"2020","unstructured":"Chatterjee NA, Tikkanen JT, Panicker GK et al (2020) Simple electrocardiographic measures improve sudden arrhythmic death prediction in coronary disease. Eur Heart J 41(21):1988\u20131999. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa177","journal-title":"Eur Heart J"},{"issue":"6","key":"10604_CR64","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3390\/cancers13061197","volume":"13","author":"J Pohl","year":"2021","unstructured":"Pohl J, Mincu RI, Mrotzek SM et al (2021) ECG Scoring for the Evaluation of Therapy-Na\u00efve Cancer Patients to Predict Cardiotoxicity. Cancers (Basel) 13(6):1197. https:\/\/doi.org\/10.3390\/cancers13061197","journal-title":"Cancers (Basel)"},{"key":"10604_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104542","volume":"151","author":"J Benjanuwattra","year":"2020","unstructured":"Benjanuwattra J, Siri-Angkul N, Chattipakorn SC, Chattipakorn N (2020) Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies. Pharmacol Res 151:104542. https:\/\/doi.org\/10.1016\/j.phrs.2019.104542","journal-title":"Pharmacol Res"},{"issue":"46","key":"10604_CR66","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035770","volume":"102","author":"YE Dean","year":"2023","unstructured":"Dean YE, Dahshan H, Motawea KR et al (2023) Anthracyclines and the risk of arrhythmias: a systematic review and meta-analysis. Medicine (Baltimore) 102(46):e35770. https:\/\/doi.org\/10.1097\/MD.0000000000035770","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10604_CR67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/01.smj.0000257382.89910.fe","volume":"100","author":"S Kilickap","year":"2007","unstructured":"Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman G (2007) Early and late arrhythmogenic effects of doxorubicin. South Med J 100(3):262\u2013265. https:\/\/doi.org\/10.1097\/01.smj.0000257382.89910.fe","journal-title":"South Med J"},{"issue":"6","key":"10604_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ph16060844","volume":"16","author":"J Kingma","year":"2023","unstructured":"Kingma J, Simard C, Drolet B (2023) Overview of cardiac arrhythmias and treatment strategies. Pharmaceuticals (Basel) 16(6):844. https:\/\/doi.org\/10.3390\/ph16060844","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"10604_CR69","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.amjcard.2016.07.049","volume":"118","author":"M Amioka","year":"2016","unstructured":"Amioka M, Sairaku A, Ochi T et al (2016) Prognostic significance of new-onset atrial fibrillation in patients with Non-Hodgkin\u2019s lymphoma treated with anthracyclines. Am J Cardiol 118(9):1386\u20131389. https:\/\/doi.org\/10.1016\/j.amjcard.2016.07.049","journal-title":"Am J Cardiol"},{"issue":"9","key":"10604_CR70","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.hrthm.2006.05.023","volume":"3","author":"JH Indik","year":"2006","unstructured":"Indik JH, Pearson EC, Fried K, Woosley RL (2006) Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 3(9):1003\u20131007. https:\/\/doi.org\/10.1016\/j.hrthm.2006.05.023","journal-title":"Heart Rhythm"},{"issue":"8","key":"10604_CR71","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.amjcard.2003.12.055","volume":"93","author":"PM Rautaharju","year":"2004","unstructured":"Rautaharju PM, Zhang ZM, Prineas R, Heiss G (2004) Assessment of prolonged QT and JT intervals in ventricular conduction defects. Am J Cardiol 93(8):1017\u20131021. https:\/\/doi.org\/10.1016\/j.amjcard.2003.12.055","journal-title":"Am J Cardiol"},{"issue":"4","key":"10604_CR72","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/01.res.76.4.645","volume":"76","author":"YX Wang","year":"1995","unstructured":"Wang YX, Korth M (1995) Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ Res 76(4):645\u2013653. https:\/\/doi.org\/10.1161\/01.res.76.4.645","journal-title":"Circ Res"},{"issue":"4","key":"10604_CR73","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ehjci\/jeaa339","volume":"22","author":"C Zito","year":"2021","unstructured":"Zito C, Manganaro R, Cusm\u00e0 Piccione M (2021) Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). Eur Heart J Cardiovasc Imaging 22(4):406\u2013415. https:\/\/doi.org\/10.1093\/ehjci\/jeaa339","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"10604_CR74","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s10741-025-10569-0","volume":"30","author":"S Sperlongano","year":"2025","unstructured":"Sperlongano S, Verde G, Guarnaccia N et al (2025) Echocardiographic monitoring in cancer therapy: clinical guidance for cardiologists and oncologists. Heart Fail Rev 30(6):1591\u20131602. https:\/\/doi.org\/10.1007\/s10741-025-10569-0","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10604_CR75","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/OP.20.00924","volume":"17","author":"JR Stone","year":"2021","unstructured":"Stone JR, Kanneganti R, Abbasi M, Akhtari M (2021) Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract 17(5):228\u2013236. https:\/\/doi.org\/10.1200\/OP.20.00924","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10604_CR76","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CM9.0000000000002222","volume":"136","author":"B Liu","year":"2023","unstructured":"Liu B, Wang Y, An T et al (2023) Knowledge level of cardio-oncology in oncologist and cardiologist: a survey in China. Chin Med J (Engl) 136(1):114\u2013116. https:\/\/doi.org\/10.1097\/CM9.0000000000002222","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"10604_CR77","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.rec.2022.12.004","volume":"76","author":"SEC Working Group for the 2022 ESC guidelines on cardio-oncology and SEC Guidelines Committee","year":"2023","unstructured":"SEC Working Group for the 2022 ESC guidelines on cardio-oncology and SEC Guidelines Committee (2023) Comments on the 2022 ESC guidelines on cardio-oncology. Rev Esp Cardiol (Engl Ed) 76(6):409\u2013416. https:\/\/doi.org\/10.1016\/j.rec.2022.12.004","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"4","key":"10604_CR78","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277\u2013314. https:\/\/doi.org\/10.1016\/j.echo.2016.01.011","journal-title":"J Am Soc Echocardiogr"},{"issue":"8","key":"10604_CR79","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ehjci\/jex033","volume":"18","author":"C Santoro","year":"2017","unstructured":"Santoro C, Arpino G, Esposito R et al (2017) 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging 18(8):930\u2013936. https:\/\/doi.org\/10.1093\/ehjci\/jex033","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"10604_CR80","doi-asserted-by":"publisher","first-page":"550","DOI":"10.6515\/acs20151023a","volume":"32","author":"WT Chang","year":"2016","unstructured":"Chang WT, Shih JY, Feng YH et al (2016) The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer. Acta Cardiol Sin 32(5):550\u2013559. https:\/\/doi.org\/10.6515\/acs20151023a","journal-title":"Acta Cardiol Sin"},{"issue":"19","key":"10604_CR81","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.112.113233","volume":"126","author":"MA Rosenberg","year":"2012","unstructured":"Rosenberg MA, Manning WJ (2012) Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation 126(19):2353\u20132362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.113233","journal-title":"Circulation"},{"issue":"1","key":"10604_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7863\/jum.2011.30.1.71","volume":"30","author":"S Mondillo","year":"2011","unstructured":"Mondillo S, Galderisi M, Mele D et al (2011) Speckle-tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med 30(1):71\u201383. https:\/\/doi.org\/10.7863\/jum.2011.30.1.71","journal-title":"J Ultrasound Med"},{"issue":"Suppl 1","key":"10604_CR83","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2459\/JCM.0000000000001422","volume":"24","author":"GE Mandoli","year":"2023","unstructured":"Mandoli GE, Cameli M, Pastore MC et al (2023) Speckle tracking echocardiography in early disease stages: a therapy modifier? J Cardiovasc Med (Hagerstown) 24(Suppl 1):e55\u2013e66. https:\/\/doi.org\/10.2459\/JCM.0000000000001422","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"5","key":"10604_CR84","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jaccao.2020.10.011","volume":"2","author":"JE Liu","year":"2020","unstructured":"Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M (2020) Strain imaging in cardio-oncology. JACC CardioOncol 2(5):677\u2013689. https:\/\/doi.org\/10.1016\/j.jaccao.2020.10.011","journal-title":"JACC CardioOncol"},{"issue":"3","key":"10604_CR85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030986","volume":"15","author":"G S\u0142awi\u0144ski","year":"2023","unstructured":"S\u0142awi\u0144ski G, Hawryszko M, Li\u017cewska-Springer A, Nabia\u0142ek-Trojanowska I, Lewicka E (2023) Global longitudinal strain in cardio-oncology: a review. Cancers (Basel) 15(3):986. https:\/\/doi.org\/10.3390\/cancers15030986","journal-title":"Cancers (Basel)"},{"issue":"41","key":"10604_CR86","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"issue":"9","key":"10604_CR87","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/ehjci\/jev113","volume":"16","author":"N Mousavi","year":"2015","unstructured":"Mousavi N, Tan TC, Ali M et al (2015) Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50\u201359% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 16(9):977\u2013984. https:\/\/doi.org\/10.1093\/ehjci\/jev113","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"10604_CR88","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11912-022-01242-y","volume":"24","author":"TH Marwick","year":"2022","unstructured":"Marwick TH (2022) Global longitudinal strain monitoring to guide cardioprotective medications during anthracycline treatment. Curr Oncol Rep 24(6):687\u2013694. https:\/\/doi.org\/10.1007\/s11912-022-01242-y","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10604_CR89","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jcmg.2018.03.019","volume":"11","author":"T Negishi","year":"2018","unstructured":"Negishi T, Thavendiranathan P, Negishi K, Marwick TH, SUCCOUR investigators (2018) Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial. JACC Cardiovasc Imaging 11(8):1098\u20131105. https:\/\/doi.org\/10.1016\/j.jcmg.2018.03.019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"41","key":"10604_CR90","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","volume":"45","author":"TH Marwick","year":"2024","unstructured":"Marwick TH, Dewar E, Nolan M, Shirazi M, Dias P, Wright L, Fitzgerald B, Kearney L, Srivastava P, Atherton J, Negishi K, Sverdlov AL, Wahi S, Otton J, Selvanayagam J, Thomas L, Thavendiranathan P (2024) Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J 45(41):4414\u20134424. https:\/\/doi.org\/10.1093\/eurheartj\/ehae574","journal-title":"Eur Heart J"},{"issue":"10","key":"10604_CR91","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","volume":"4","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou EK, Kokkinidis DG, Kampaktsis PN et al (2019) Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 4(10):1007\u20131018. https:\/\/doi.org\/10.1001\/jamacardio.2019.2952","journal-title":"JAMA Cardiol"},{"key":"10604_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-025-10495-1","author":"A Mecinaj","year":"2025","unstructured":"Mecinaj A, Vinje-Jakobsen V, Ngo DTM, Sverdlov AL, Myhre PL (2025) The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-025-10495-1","journal-title":"Heart Fail Rev"},{"issue":"D","key":"10604_CR93","doi-asserted-by":"publisher","first-page":"D3","DOI":"10.1093\/eurheartjsupp\/suad111.009","volume":"25","author":"A Faggiano","year":"2023","unstructured":"Faggiano A, Giangiacomi F, Gherbesi E et al (2023) C9 The effect of anthracycline chemotherapy on peak left atrial longitudinal strain: a metaanalysis. Eur Heart J Suppl 25(D):D3\u2013D3","journal-title":"Eur Heart J Suppl"},{"issue":"25 Pt A","key":"10604_CR94","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim KD et al (2014) Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 63(25 Pt A):2751\u20132768. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.073","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10604_CR95","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1139\/cjpp-2012-0398","volume":"91","author":"C Morno\u015f","year":"2013","unstructured":"Morno\u015f C, Petrescu L (2013) Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol 91(8):601\u2013607. https:\/\/doi.org\/10.1139\/cjpp-2012-0398","journal-title":"Can J Physiol Pharmacol"},{"issue":"4","key":"10604_CR96","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ehjci\/jew041","volume":"17","author":"Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults","year":"2016","unstructured":"Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults (2016) An Update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 17(4):412. https:\/\/doi.org\/10.1093\/ehjci\/jew041","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"22","key":"10604_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12227127","volume":"12","author":"D Di Lisi","year":"2023","unstructured":"Di Lisi D, Moreo A, Casavecchia G et al (2023) Atrial strain assessment for the early detection of cancer therapy-related cardiac dysfunction in breast cancer women (the STRANO STUDY: atrial strain in cardio-oncology). J Clin Med 12(22):7127. https:\/\/doi.org\/10.3390\/jcm12227127","journal-title":"J Clin Med"},{"issue":"9","key":"10604_CR98","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J \u010celutkien\u0117","year":"2020","unstructured":"\u010celutkien\u0117 J, Pudil R, L\u00f3pez-Fern\u00e1ndez T et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 22(9):1504\u20131524. https:\/\/doi.org\/10.1002\/ejhf.1957","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10604_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223883","volume":"16","author":"A Faggiano","year":"2024","unstructured":"Faggiano A, Gherbesi E, Giordano C et al (2024) Anthracycline-induced subclinical right ventricular dysfunction in breast cancer patients: a systematic review and meta-analysis. Cancers (Basel) 16(22):3883. https:\/\/doi.org\/10.3390\/cancers16223883","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10604_CR100","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/ehjci\/jeaa351","volume":"22","author":"S Rosmini","year":"2021","unstructured":"Rosmini S, Aggarwal A, Chen DH et al (2021) Cardiac computed tomography in cardio-oncology: an update on recent clinical applications. Eur Heart J Cardiovasc Imaging 22(4):397\u2013405. https:\/\/doi.org\/10.1093\/ehjci\/jeaa351","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"10604_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-024-00266-6","volume":"10","author":"A Borowiec","year":"2024","unstructured":"Borowiec A, Ozdowska P, Rosinska M et al (2024) Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicity. Cardiooncology 10(1):64. https:\/\/doi.org\/10.1186\/s40959-024-00266-6","journal-title":"Cardiooncology"},{"key":"10604_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110498","volume":"200","author":"Y Xie","year":"2024","unstructured":"Xie Y, Shen H, Xu Q et al (2024) Evaluating coronary arteries and predicting MACEs using CCTA in lung cancer patients receiving chemotherapy or chemoradiotherapy. Radiother Oncol 200:110498. https:\/\/doi.org\/10.1016\/j.radonc.2024.110498","journal-title":"Radiother Oncol"},{"key":"10604_CR103","doi-asserted-by":"publisher","first-page":"100119","DOI":"10.1016\/j.ajpc.2020.100119","volume":"4","author":"FM Wang","year":"2020","unstructured":"Wang FM, Reiter-Brennan C, Dardari Z et al (2020) Association between coronary artery calcium and cardiovascular disease as a supporting cause in cancer: The CAC consortium. Am J Prev Cardiol 4:100119. https:\/\/doi.org\/10.1016\/j.ajpc.2020.100119","journal-title":"Am J Prev Cardiol"},{"issue":"5","key":"10604_CR104","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jaccao.2021.09.010","volume":"3","author":"JC Lopez-Mattei","year":"2021","unstructured":"Lopez-Mattei JC, Yang EH et al (2021) Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer. JACC CardioOncol 3(5):635\u2013649. https:\/\/doi.org\/10.1016\/j.jaccao.2021.09.010","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10604_CR105","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.prro.2023.08.008","volume":"13","author":"JL Wright","year":"2023","unstructured":"Wright JL, Amini A, Bergom C, Milgrom SA (2023) Summary of cardiac computed tomographic imaging in cardio-oncology: an expert consensus document of the Society of Cardiovascular Computed Tomography. Pract Radiat Oncol 13(6):488\u2013495. https:\/\/doi.org\/10.1016\/j.prro.2023.08.008","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"10604_CR106","doi-asserted-by":"publisher","first-page":"103021","DOI":"10.1016\/j.cpcardiol.2025.103021","volume":"50","author":"L Bergamaschi","year":"2025","unstructured":"Bergamaschi L, De Vita A, Villano A, Coronary Physiopathology and Microcirculation Working Group of the Italian Society of Cardiology (SIC) et al (2025) Non-invasive imaging assessment in angina with non-obstructive coronary arteries (ANOCA). Curr Probl Cardiol 50(5):103021. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103021","journal-title":"Curr Probl Cardiol"},{"issue":"3","key":"10604_CR107","doi-asserted-by":"publisher","first-page":"610","DOI":"10.21037\/cdt-20-165","volume":"10","author":"MK Burrage","year":"2020","unstructured":"Burrage MK, Ferreira VM (2020) The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology. Cardiovasc Diagn Ther 10(3):610\u2013624. https:\/\/doi.org\/10.21037\/cdt-20-165","journal-title":"Cardiovasc Diagn Ther"},{"issue":"6","key":"10604_CR108","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1007\/s12350-018-1293-9","volume":"25","author":"AI L\u00f6ffler","year":"2018","unstructured":"L\u00f6ffler AI, Salerno M (2018) Cardiac MRI for the evaluation of oncologic cardiotoxicity. J Nucl Cardiol 25(6):2148\u20132158. https:\/\/doi.org\/10.1007\/s12350-018-1293-9","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"10604_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-020-00682-4","volume":"22","author":"T Leiner","year":"2020","unstructured":"Leiner T, Bogaert J, Friedrich MG et al (2020) SCMR position paper (2020) on clinical indications for cardiovascular magnetic resonance. J Cardiovasc Magn Reson 22(1):76. https:\/\/doi.org\/10.1186\/s12968-020-00682-4","journal-title":"J Cardiovasc Magn Reson"},{"issue":"8","key":"10604_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13081437","volume":"13","author":"K Michler","year":"2023","unstructured":"Michler K, Hessman C, Pr\u00fcmmer M et al (2023) Cardiac MRI: an alternative method to determine the left ventricular function. Diagnostics (Basel) 13(8):1437. https:\/\/doi.org\/10.3390\/diagnostics13081437","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10604_CR111","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jaccao.2023.06.006","volume":"5","author":"ER Rashed","year":"2023","unstructured":"Rashed ER, Margulies KB (2023) New cardiotoxicity risk assessment guidelines: searching for validation. JACC CardioOncol 5(5):638\u2013640. https:\/\/doi.org\/10.1016\/j.jaccao.2023.06.006","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10604_CR112","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12968-015-0111-7","volume":"17","author":"N Kawel-Boehm","year":"2015","unstructured":"Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER et al (2015) Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson 17(1):29. https:\/\/doi.org\/10.1186\/s12968-015-0111-7","journal-title":"J Cardiovasc Magn Reson"},{"issue":"11","key":"10604_CR113","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","volume":"110","author":"TG Neilan","year":"2012","unstructured":"Neilan TG, Coelho-Filho OR, Pena-Herrera D et al (2012) Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 110(11):1679\u20131686. https:\/\/doi.org\/10.1016\/j.amjcard.2012.07.040","journal-title":"Am J Cardiol"},{"issue":"1","key":"10604_CR114","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10334-005-0025-8","volume":"19","author":"S Clay","year":"2006","unstructured":"Clay S, Alfakih K, Radjenovic A et al (2006) Normal range of human left ventricular volumes and mass using steady state free precession MRI in the radial long axis orientation. MAGMA 19(1):41\u201345. https:\/\/doi.org\/10.1007\/s10334-005-0025-8","journal-title":"MAGMA"},{"issue":"6","key":"10604_CR115","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1093\/ehjci\/jeae025","volume":"25","author":"G Kasa","year":"2024","unstructured":"Kasa G, Teis A, Junc\u00e0 G et al (2024) Clinical and prognostic implications of left ventricular dilatation in heart failure. Eur Heart J Cardiovasc Imaging 25(6):849\u2013856. https:\/\/doi.org\/10.1093\/ehjci\/jeae025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10604_CR116","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005234","volume":"12","author":"MS Willis","year":"2019","unstructured":"Willis MS, Parry TL, Brown DI et al (2019) Doxorubicin exposure causes subacute cardiac atrophy dependent on the striated muscle-specific ubiquitin ligase MuRF1. Circ Heart Fail 12(3):e005234. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005234","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10604_CR117","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","volume":"11","author":"JH Jordan","year":"2018","unstructured":"Jordan JH, Castellino SM, Mel\u00e9ndez GC et al (2018) Left ventricular mass change after anthracycline chemotherapy. Circ Heart Fail 11(7):e004560. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004560","journal-title":"Circ Heart Fail"},{"key":"10604_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.903719","volume":"9","author":"L Mabudian","year":"2022","unstructured":"Mabudian L, Jordan JH, Bottinor W, Hundley WG (2022) Cardiac MRI assessment of anthracycline-induced cardiotoxicity. Front Cardiovasc Med 9:903719. https:\/\/doi.org\/10.3389\/fcvm.2022.903719","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10604_CR119","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.014068","volume":"16","author":"KE Thomas","year":"2023","unstructured":"Thomas KE, Fotaki A, Botnar RM, Ferreira VM (2023) Imaging methods: magnetic resonance imaging. Circ Cardiovasc Imaging 16(1):e014068. https:\/\/doi.org\/10.1161\/CIRCIMAGING.122.014068","journal-title":"Circ Cardiovasc Imaging"},{"issue":"9","key":"10604_CR120","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/ehjci\/jeu050","volume":"15","author":"A Florian","year":"2014","unstructured":"Florian A, Ludwig A, R\u00f6sch S et al (2014) Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging. Eur Heart J Cardiovasc Imaging 15(9):1004\u20131012. https:\/\/doi.org\/10.1093\/ehjci\/jeu050","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10604_CR121","doi-asserted-by":"publisher","first-page":"598","DOI":"10.21037\/cdt.2019.12.09","volume":"10","author":"AJM Lewis","year":"2020","unstructured":"Lewis AJM, Burrage MK, Ferreira VM (2020) Cardiovascular magnetic resonance imaging for inflammatory heart diseases. Cardiovasc Diagn Ther 10(3):598\u2013609. https:\/\/doi.org\/10.21037\/cdt.2019.12.09","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"10604_CR122","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaccao.2021.04.011","volume":"3","author":"R O\u2019Quinn","year":"2021","unstructured":"O\u2019Quinn R, Ferrari VA, Daly R et al (2021) Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization. JACC CardioOncol 3(2):191\u2013200. https:\/\/doi.org\/10.1016\/j.jaccao.2021.04.011","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10604_CR123","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s12350-022-03154-7","volume":"30","author":"J Nordstr\u00f6m","year":"2023","unstructured":"Nordstr\u00f6m J, Kvernby S, Kero T et al (2023) Left-ventricular volumes and ejection fraction from cardiac ECG-gated 15O-water positron emission tomography compared to cardiac magnetic resonance imaging using simultaneous hybrid PET\/MR. J Nucl Cardiol 30(4):1352\u20131362. https:\/\/doi.org\/10.1007\/s12350-022-03154-7","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10604_CR124","doi-asserted-by":"publisher","first-page":"114","DOI":"10.14797\/mdcj-16-2-114","volume":"16","author":"KC El-Tallawi","year":"2020","unstructured":"El-Tallawi KC, Aljizeeri A, Nabi F, Al-Mallah MH (2020) Myocardial Perfusion Imaging Using Positron Emission Tomography. Methodist Debakey Cardiovasc J 16(2):114\u2013121. https:\/\/doi.org\/10.14797\/mdcj-16-2-114","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"6","key":"10604_CR125","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5144\/0256-4947.2007.415","volume":"27","author":"H Demir","year":"2007","unstructured":"Demir H, Tan YZ, Kozdag G et al (2007) Comparison of gated SPECT, echocardiography and cardiac magnetic resonance imaging for the assessment of left ventricular ejection fraction and volumes. Ann Saudi Med 27(6):415\u2013420. https:\/\/doi.org\/10.5144\/0256-4947.2007.415","journal-title":"Ann Saudi Med"},{"key":"10604_CR126","doi-asserted-by":"publisher","unstructured":"Tsj O, Rjj K, Jh C, M W, Fm VZ (2018) Myocardial blood flow and myocardial flow reserve values in 13N-ammonia myocardial perfusion PET\/CT using a time-efficient protocol in patients without coronary artery disease. Eur J Hybrid Imaging 2(1):11. https:\/\/doi.org\/10.1186\/s41824-018-0029-z","DOI":"10.1186\/s41824-018-0029-z"},{"issue":"10","key":"10604_CR127","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s12149-020-01519-x","volume":"34","author":"O Manabe","year":"2020","unstructured":"Manabe O, Naya M, Aikawa T, Tamaki N (2020) Recent advances in cardiac positron emission tomography for quantitative perfusion analyses and molecular imaging. Ann Nucl Med 34(10):697\u2013706. https:\/\/doi.org\/10.1007\/s12149-020-01519-x","journal-title":"Ann Nucl Med"},{"issue":"12","key":"10604_CR128","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s11604-024-01636-x","volume":"42","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Manabe O, Hirata K (2024) Cardiovascular imaging in cardio-oncology. Jpn J Radiol 42(12):1372\u20131380. https:\/\/doi.org\/10.1007\/s11604-024-01636-x","journal-title":"Jpn J Radiol"},{"issue":"6","key":"10604_CR129","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s12350-019-01617-y","volume":"27","author":"J Kim","year":"2020","unstructured":"Kim J, Cho SG, Kang SR et al (2020) Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol 27(6):2154\u20132163. https:\/\/doi.org\/10.1007\/s12350-019-01617-y","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"10604_CR130","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11897-022-00544-3","volume":"19","author":"MI Printezi","year":"2022","unstructured":"Printezi MI, Yousif LIE, Kamphuis JAM et al (2022) LVEF by multigated acquisition scan compared to other imaging modalities in cardio-oncology: a systematic review. Curr Heart Fail Rep 19(3):136\u2013145. https:\/\/doi.org\/10.1007\/s11897-022-00544-3","journal-title":"Curr Heart Fail Rep"},{"issue":"5","key":"10604_CR131","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.hlc.2024.03.010","volume":"33","author":"MT Nolan","year":"2024","unstructured":"Nolan MT, Pathan F, Nott L, Black A, Pointon O, Marwick TH (2024) Comparison of echocardiography and multi-planar gated acquisition scans for predicting cancer-treatment-related cardiovascular dysfunction. Heart Lung Circ 33(5):693\u2013703. https:\/\/doi.org\/10.1016\/j.hlc.2024.03.010","journal-title":"Heart Lung Circ"},{"key":"10604_CR132","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yjmcc.2022.03.010","volume":"167","author":"Y Kim","year":"2022","unstructured":"Kim Y, Seidman JG, Seidman CE (2022) Genetics of cancer therapy-associated cardiotoxicity. J Mol Cell Cardiol 167:85\u201391. https:\/\/doi.org\/10.1016\/j.yjmcc.2022.03.010","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10604_CR133","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","volume":"140","author":"P Garcia-Pavia","year":"2019","unstructured":"Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA et al (2019) Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation 140(1):31\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037934","journal-title":"Circulation"},{"key":"10604_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.867873","volume":"9","author":"TK Al-Otaibi","year":"2022","unstructured":"Al-Otaibi TK, Weitzman B, Tahir UA, Asnani A (2022) Genetics of anthracycline-associated cardiotoxicity. Frontiers in Cardiovascular Medicine 9:867873. https:\/\/doi.org\/10.3389\/fcvm.2022.867873","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"10604_CR135","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cardfail.2015.09.012","volume":"21","author":"B Greenberg","year":"2015","unstructured":"Greenberg B, Butler J, Felker GM et al (2015) CUPID 2: a phase 2b trial investigating the efficacy and safety of the intracoronary administration of AAV1\/SERCA2a in patients with advanced heart failure. J Card Fail 21:939\u2013940. https:\/\/doi.org\/10.1016\/j.cardfail.2015.09.012","journal-title":"J Card Fail"},{"issue":"10","key":"10604_CR136","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.19401\/j.cnki.1007-3639.2022.10.010","volume":"32","author":"Z Shen","year":"2022","unstructured":"Shen Z, Shao Z (2022) Chinese consensus of cardio-oncology in breast cancer. China Oncol 32(10):1016\u20131036. https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2022.10.010","journal-title":"China Oncol"},{"issue":"18","key":"10604_CR137","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS et al (2020) Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41(18):1733\u20131743. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051","journal-title":"Eur Heart J"},{"key":"10604_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2024.100479","volume":"48","author":"G Echefu","year":"2024","unstructured":"Echefu G, Shah R, Sanchez Z, Rickards J, Brown SA (2024) Artificial intelligence: applications in cardio-oncology and potential impact on racial disparities. American Heart Journal Plus: Cardiology Research and Practice 48:100479. https:\/\/doi.org\/10.1016\/j.ahjo.2024.100479","journal-title":"American Heart Journal Plus: Cardiology Research and Practice"},{"key":"10604_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100129","volume":"15","author":"DS Martinez","year":"2022","unstructured":"Martinez DS, Noseworthy PA, Akbilgic O et al (2022) Artificial intelligence opportunities in cardio-oncology: overview with spotlight on electrocardiography. American Heart Journal Plus: Cardiology Research and Practice 15:100129. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100129","journal-title":"American Heart Journal Plus: Cardiology Research and Practice"},{"key":"10604_CR140","doi-asserted-by":"publisher","DOI":"10.2196\/63964","author":"H Mushcab","year":"2025","unstructured":"Mushcab H, Al Ramis M, AlRujaib A et al (2025) Application of artificial intelligence in cardio-oncology imaging for cancer therapy-related cardiovascular toxicity: a systematic review. JMIR Cancer. https:\/\/doi.org\/10.2196\/63964","journal-title":"JMIR Cancer"},{"key":"10604_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-025-02215-w","author":"A Guha","year":"2025","unstructured":"Guha A, Shah V, Nahle T et al (2025) Artificial intelligence applications in cardio-oncology: a comprehensive review. Curr Cardiol Rep. https:\/\/doi.org\/10.1007\/s11886-025-02215-w","journal-title":"Curr Cardiol Rep"},{"key":"10604_CR142","doi-asserted-by":"publisher","unstructured":"Khera R, Asnani AH, Krive J, American Heart Association Cardio-Oncology and Data Science and Precision Medicine Committees of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular and Stroke Nursing et al (2025) Artificial intelligence to enhance precision medicine in cardio-oncology: a scientific statement from the American Heart Association. Circ Genom Precis Med e000097. https:\/\/doi.org\/10.1161\/HCG.0000000000000097","DOI":"10.1161\/HCG.0000000000000097"},{"key":"10604_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100129","volume":"15","author":"DS Martinez","year":"2022","unstructured":"Martinez DS, Noseworthy PA, Akbilgic O, Herrmann J, Ruddy KJ, Hamid A, Maddula R, Singh A, Davis R, Gunturkun F, Jefferies JL, Brown SA (2022) Artificial intelligence opportunities in cardio-oncology: overview with spotlight on electrocardiography. Am Heart J Plus 15:100129. https:\/\/doi.org\/10.1016\/j.ahjo.2022.100129","journal-title":"Am Heart J Plus"},{"issue":"2","key":"10604_CR144","doi-asserted-by":"publisher","first-page":"3","DOI":"10.18087\/CARDIO.2025.2.N2879","volume":"65","author":"Y Belenkov","year":"2025","unstructured":"Belenkov Y, Kozhevnikova M, Khabarova N et al (2025) The role of artificial intelligence in cardiology. Kardiologiia 65(2):3\u201316. https:\/\/doi.org\/10.18087\/CARDIO.2025.2.N2879","journal-title":"Kardiologiia"},{"issue":"5","key":"10604_CR145","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurjpc\/zwad348","volume":"31","author":"JEJ Jacobs","year":"2024","unstructured":"Jacobs JEJ, Greason G, Mangold KE et al (2024) Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy. Eur J Prev Cardiol 31(5):560\u2013566. https:\/\/doi.org\/10.1093\/eurjpc\/zwad348","journal-title":"Eur J Prev Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10604-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10604-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10604-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:12:22Z","timestamp":1773972742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10604-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":145,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10604"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10604-8","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ashot Avagimyan is the first author of this submission and it is a part of his Doctor of Science (DSc) in Medicine degree.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}